{
    "organizations": [],
    "uuid": "7efb901103a74d90ffafe011fb026dd8fbfa2c7c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-earns-ind/brief-five-prime-therapeutics-earns-ind-milestone-payment-under-immune-checkpoint-pathways-discovery-collaboration-with-bristol-myers-squibb-idUSFWN1P30LY",
    "ord_in_thread": 0,
    "title": "BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Five Prime Therapeutics Inc:\n* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME\n* FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME\n* FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019\n* FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T22:05:00.000+02:00",
    "crawled": "2018-01-09T17:18:39.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "five",
        "prime",
        "therapeutic",
        "earns",
        "ind",
        "milestone",
        "payment",
        "immune",
        "checkpoint",
        "pathway",
        "discovery",
        "collaboration",
        "squibb",
        "announces",
        "bm",
        "extended",
        "research",
        "term",
        "collaboration",
        "second",
        "time",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "milestone",
        "antibody",
        "targeting",
        "trigger",
        "million",
        "payment",
        "five",
        "prime",
        "five",
        "bm",
        "extends",
        "research",
        "collaboration",
        "term",
        "development",
        "commercialization",
        "therapeutic",
        "immune",
        "checkpoint",
        "pathway",
        "march",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "squibb",
        "also",
        "provide",
        "additional",
        "funding",
        "five",
        "prime",
        "extended",
        "term",
        "research",
        "collaboration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}